Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PRT7732

Small molecule · Degrader of SMARCA2 (BRM) (SMARCA2) · developed by Prelude Therapeutics

Phase 1 Most advanced trial (none active)
PRLD Developer
1 Registered trials

What is PRT7732?

PRT7732 is an orally bioavailable targeted protein degrader that links a SMARCA2-binding moiety to an E3 ubiquitin ligase-binding moiety. It forms a ternary complex that drives proteasomal degradation of SMARCA2, disrupting the SWI/SNF chromatin remodeling complex in SMARCA4-deleted cancers. It is being studied in solid tumors, including non-small cell lung carcinoma and esophagogastric carcinomas.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
SMARCA2 (BRM) (SMARCA2), E3 ubiquitin ligase (binding partner it blocks), SMARCA4 (BRG1) deletion (SMARCA4) (biomarker)
Mechanism
Degrader of SMARCA2 (BRM) (SMARCA2)
Pathways
SWI/SNF (BAF) chromatin remodeling, ubiquitin-proteasome degradation, oncogenic gene expression
Therapy area
Oncology
Developer
Prelude Therapeutics Incorporated (PRLD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06560645 Phase 1 Advanced Solid Tumor Terminated PRLD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorEsophageal AdenocarcinomaEsophageal Squamous Cell CarcinomaGastric AdenocarcinomaGastric Squamous Cell CarcinomaGastroesophageal Junction AdenocarcinomaGastroesophageal Junction Squamous Cell CarcinomaMetastatic Solid TumorNon-small Cell Lung CarcinomaSMARCA4 Mutation

Other drugs acting on SMARCA2

More from Prelude Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PRLD page.

Follow PRLD, the company behind PRT7732

See PRLD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PRLD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.